Cooley LLP (JD Supra China)

Since the outbreak of the coronavirus disease (COVID-19), the China central government has issued policies and guidelines in various aspects to help enterprises and individuals during the epidemic. Following the central government's step and within the central government's framework, the local governments at provincial and/or municipal levels have also published policies and implementation rules...

In conjunction with our Q4 Venture Financing Report, I sat down with Nisa Leung from Qiming Venture Partners to get her take on the state of venture capital investing. It is worth acknowledging that at the time of drafting the interview questions, coronavirus was just beginning to appear in China. By the time we went to publish this interview, it was a significant factor in the state of venture...

In an important development for the best choice of a seat, or legal place, of arbitration in Asia, the “Arrangement Concerning Mutual Assistance in Court-ordered Interim Measures in Aid of Arbitral Proceedings by the Courts of the Mainland and of the HKSAR” entered into effect on October 1, 2019.

On 28 June, 2018, the National Development and Reform Commission (NDRC) and the Ministry of Commerce (MOFCOM) of the People’s Republic of China (PRC) jointly issued the Special Administrative Measures on Access to Foreign Investment (the “Negative List”) (2018 Version). Effective on July 28, 2018, the Negative List supersedes the Foreign Investment Industry Guidance Catalogue (2017 Version) (the “

On October 8, 2017, the General Office of the CPC Central Committee and the General Office of China's State Council jointly issued Opinions of the State Council on Promulgating the Reform of Review and Approval System for Drugs and Medical Devices to Encourage Innovation (the Opinion). This alert is to provide you with a high-level summary of the latest Opinion on Reform of the Review and...

On June 28, 2017, the National Development and Reform Commission (NDRC) and the Ministry of Commerce (MOFCOM) of the People's Republic of China (PRC) jointly issued the Foreign Investment Industry Guidance Catalogue (2017 Version) (the 2017 Catalogue) to supersede the Foreign Investment Industry Guidance Catalogue (2015 Version) (the 2015 Catalogue). The 2017 Catalogue will become effective on...

The "Administrative Measures for the Registration of Medical Device" (Registration Measures) was issued by the China Food and Drug Administration (CFDA) and became effective on October 1, 2014. According to the Registration Measures, Class II and Class III devices meeting the following criteria are exempt from clinical trial requirement:devices that have been sold and used for years without...

The Chinese central government has taken several important steps in reforming the drug approval system in China, which could have far-reaching implications for pharmaceutical companies in China as well as foreign companies that are interested in commercializing their products in China.

After months of research and vetting, you’ve finally settled on a good contract manufacturer (CM) in China that offers the best quality and price combo and has a solid track record and now it’s time to cement the relationship with a supply agreement. Thanks to globalization and outsourcing, a lot of CMs in China today are large and sophisticated, but many of them still like to use supply...